Enzyme News and Research

RSS

New model reveals molecular basis of multiple hereditary exostoses

Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement.

2 Jun 2010

University of California scientists identify new kinase that regulates cell proliferation, migration

Scientists at the University of California, San Diego have identified a previously unknown kinase that regulates cell proliferation, shape and migration, and may play a major role in the progression or metastasis of cancer cells.

1 Jun 2010

Commonalities between flies and humans make valuable new model for galactosemia

Galactosemia is a metabolic disease resulting from an inherited defect that prevents the proper metabolism of galactose, a sugar commonly found in dairy products, like milk. Exposure of affected people to galactose, can damage most of their organ systems and can be fatal. The ability to study the disease is limited by a lack of animal models.

1 Jun 2010

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

Major response to preoperative therapy increases survival in pancreatic cancer patients

Cancer of the pancreas--a glandular organ that lies behind the stomach and secretes vital enzymes and hormones--seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

29 May 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Nihal Altan-Bonnet, assistant professor of cell biology, Rutgers University in Newark, and her research team have made a significant new discovery about RNA viruses and how they replicate themselves.

29 May 2010

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

DFG approves establishment of twelve new CRCs

The Deutsche Forschungsgemeinschaft has approved the establishment of twelve new Collaborative Research Centres beginning 1 July 2010. This was decided by the responsible Grants Committee at its spring meeting in Bonn. The new CRCs will initially be funded for four years with a total of 112 million euros (including a 20% programme allowance for indirect project costs).

29 May 2010

Life Technologies acquires majority stake in Geneart

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.

28 May 2010

Thermo Fisher Scientific to acquire Fermentas International for $260M

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has signed a definitive agreement to acquire Fermentas International Inc. - a manufacturer and global distributor of enzymes, reagents and kits for molecular and cellular biology research - for $260 million in cash, subject to a post-closing adjustment. With headquarters in Burlington, Ontario, and principal operations in Vilnius, Lithuania, Fermentas has approximately 500 employees.

From Thermo Fisher Scientific Inc. 28 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

UCSF research shows brief exercise buffers the effects of stress-induced cell aging

Exercise can buffer the effects of stress-induced cell aging, according to new research from UCSF that revealed actual benefits of physical activity at the cellular level.

27 May 2010

Drug and dosage influence risk of GI bleeding

A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.

27 May 2010

Researchers use new imaging technique to view microvessels in the brains of living mice

Researchers at Northwestern University Feinberg School of Medicine have identified in mice a previously unknown protective mechanism by which the smallest blood vessels remove blood clots and other blockages from the brain. The findings provide insights into mechanisms that may be involved in age-related cognitive decline, Alzheimer's disease and recovery from stroke.

27 May 2010

Good number of natural bypass vessels an 'insurance policy' against blockage

When the arteries delivering oxygen to our vital organs are obstructed by atherosclerosis or clots, the result is almost always a stroke, heart attack or damage to a peripheral tissue such as the legs (peripheral artery disease). But the severity of tissue injury or destruction from a choked-off blood supply varies from person to person, and may depend in large part on whose circulatory system has the best back-up plan to provide alternate routes of circulation.

26 May 2010

UT Southwestern Medical Center researchers identify novel chemical compounds with anti-malarial activity

As part of a multicenter study, UT Southwestern Medical Center researchers have identified a series of chemical compounds that might serve as starting points for the identification of new classes of anti-malarial drugs.

26 May 2010

Increasing levels of GGA3 protein prevent accumulation of enzyme linked to Alzheimer's disease

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer's disease. The team found that increasing levels of the protein (called GGA3) prevented the accumulation of an enzyme linked to Alzheimer's. The strategy may lead to new treatments for the neurodegenerative disease.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Lumizyme receives FDA approval for patients with late-onset Pompe disease

The U.S. Food and Drug Administration approved Lumizyme (alglucosidase alfa) for patients ages 8 years and older with late-onset (non-infantile) Pompe disease, a rare genetic disorder.

26 May 2010

Enzyme News and Research

New model reveals molecular basis of multiple hereditary exostoses

University of California scientists identify new kinase that regulates cell proliferation, migration

Commonalities between flies and humans make valuable new model for galactosemia

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Major response to preoperative therapy increases survival in pancreatic cancer patients

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

DFG approves establishment of twelve new CRCs

Life Technologies acquires majority stake in Geneart

Thermo Fisher Scientific to acquire Fermentas International for $260M

PCA-Rx represents next generation of chelation technology for ASD patients

UCSF research shows brief exercise buffers the effects of stress-induced cell aging

Drug and dosage influence risk of GI bleeding

Researchers use new imaging technique to view microvessels in the brains of living mice

Good number of natural bypass vessels an 'insurance policy' against blockage

UT Southwestern Medical Center researchers identify novel chemical compounds with anti-malarial activity

Increasing levels of GGA3 protein prevent accumulation of enzyme linked to Alzheimer's disease

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Lumizyme receives FDA approval for patients with late-onset Pompe disease

Biochemistry eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News